[Form 4] Sanara MedTech Inc. Insider Trading Activity

Rhea-AI Filing Summary

Sanara MedTech Inc. (SMTI) reported a grant of restricted common stock to CEO Seth D. Yon. The Form 4 shows the reporting person was granted 28,563 restricted shares on 09/15/2025 at no cash price, increasing his beneficial ownership to 89,851 shares. The restricted stock award was made under the company's 2024 Omnibus Long-Term Incentive Plan and vests in three equal installments on 09/15/2026, 09/15/2027 and 09/15/2028, contingent on continued employment through each vesting date. The filing is a routine Section 16 disclosure documenting the grant and resulting ownership position.

Positive

• Grant disclosed transparently: Form 4 records the restricted stock award and resulting beneficial ownership.
• Clear vesting schedule: Shares vest in three equal installments on 09/15/2026, 09/15/2027 and 09/15/2028.

Negative

• None.

Insights

Financial Analyst

TL;DR: CEO received a time‑based restricted stock grant of 28,563 shares, raising total beneficial holdings to 89,851 shares.

The Form 4 documents a standard equity compensation event: a 28,563 share restricted stock award under the 2024 Omnibus Long‑Term Incentive Plan. The award is time‑vested in three equal tranches over 2026–2028 and was granted at a reported price of $0, consistent with restricted stock treatment. This disclosure changes reported insider ownership levels but contains no operational or financial performance metrics.

Corporate Governance Expert

TL;DR: This is a routine, time‑based CEO equity grant disclosed under Section 16; vesting is tied to continued employment.

The filing specifies that the restricted shares vest one‑third on each of 09/15/2026, 09/15/2027 and 09/15/2028, conditional on employment through each date. The disclosure identifies the instrument, vesting schedule and resulting beneficial ownership of 89,851 shares, meeting Form 4 reporting requirements. No amendments, derivative transactions, or additional contingencies are disclosed in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Yon Seth D

(Last) (First) (Middle)

1200 SUMMIT AVE

SUITE 414

(Street)

FORT WORTH TX 76102

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sanara MedTech Inc. [ SMTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2025		A		28,563(1)	A	$0(1)	89,851	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest in three equal installments, with one-third of the shares vesting on September 15, 2026, 2027 and 2028, respectively, provided that the reporting person is employed by the Issuer through each such date.

	/s/ Seth D. Yon	09/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Sanara MedTech's CEO (SMTI) receive in the Form 4 filed 09/16/2025?

The CEO, Seth D. Yon, was granted 28,563 restricted shares of Sanara MedTech common stock on 09/15/2025.

How many shares does the reporting person beneficially own after the transaction?

Following the reported transaction the reporting person beneficially owns 89,851 shares.

What is the vesting schedule for the restricted shares awarded to the CEO?

The restricted stock vests in three equal installments on 09/15/2026, 09/15/2027 and 09/15/2028, subject to continued employment.

Under which plan were the restricted shares granted?

The shares were granted under the Sanara MedTech Inc. 2024 Omnibus Long‑Term Incentive Plan.

Was any cash paid for the restricted shares according to the filing?

The Form 4 reports a price of $0 for the restricted shares, consistent with a restricted stock grant.